In this episode, Dennis Walker speaks with Dr. Jonathan Fields, an integrative medicine specialist who is currently petitioning the DEA to respect the ‘Right to Try Laws’ in relation to empowering terminally ill patients to legally access psilocybin therapy.
To gain insight into the subtle distinctions between psilocybin and DMT, it is essential to explore their primary chemical similarities. Both belong to the tryptamine family, which encompasses naturally occurring neurotransmitters such as serotonin in addition to multiple psychedelic substances found in plants and fungi; yet there persists one noteworthy distinction: their metabolic properties.
In this episode of the Psychedelic Spotlight podcast, we feature…
July 21, 2021- This week’s Psychedelic Business News top stories…
This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon.
Researchers hope to establish whether the effects of microdosing are as profound as people say they are, since previous studies could not rule out placebo effect.
We speak with Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
